BioPharmSignal logoBioPharmSignal

Biotech News

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Beam Therapeutics (BEAM)Beam TherapeuticsCompany update

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Wells

Related news

BEAMBeam Therapeutics2026-07-23 11:00 EST

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

BEAMBeam Therapeutics2026-05-18 20:00 EST

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

View all latest news

Beam Therapeutics

Base Editing Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities. BEAM-302 BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is...

Recent company news

BEAMBeam Therapeutics2026-09-08 10:00 EST

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

BEAMBeam Therapeutics2026-09-01 11:00 EST

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

BEAMBeam Therapeutics2026-08-31 11:00 EST

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

BEAMBeam Therapeutics2026-08-04 11:00 EST

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

BEAMBeam Therapeutics2026-07-23 11:00 EST

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Stock data

Close
24.67 USD
Market cap
2.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States